No Data
On November 5th, buybacks were organized, with hsbc holdings, aia, among others, repurchasing shares, with hsbc holdings spending 0.224 billion Hong Kong dollars.
According to the disclosure documents released by hkex on November 6, hsbc holdings (00005.HK) and aia (01299.HK) repurchased shares. ① Hsbc holdings (00005.HK) repurchased 3.1168 million shares of common stock on November 4, involving an amount of 0.224 billion Hong Kong dollars, with a repurchase price per share ranging from 71.95 Hong Kong dollars to 71.6 Hong Kong dollars. ② Aia (01299.HK) repurchased 0.9928 million shares of common stock on November 5, involving an amount of 61.8607 million Hong Kong dollars, with a repurchase price per share ranging from 62.8 Hong Kong dollars to
Green Bamboo Biology-B (02480) spent 0.4824 million Hong Kong dollars to repurchase 0.024 million shares on November 5th.
Lushan Bio-B (02480) issued an announcement, on November 5, 2024, the company invested 0.4824 million...
Express News | Beijing Science Sun Pharmaceutical: plans to selectively sell its shares in Lvzhuo Biotech and Kang Le Weishi stocks.
Sudden Movement Spotlight | Biomedical Class B shares rose in the afternoon, LKYG-B up 30%, institutions bullish on sector further recovery space
Biomedical Class B shares rose in the afternoon, as of the time of publication, Lai Kai Medicine-B rose by 27.88%, to 7.89 Hong Kong dollars; YimingAngke-B rose by 17.91%, to 5.86 Hong Kong dollars; Yasheng Medicine-B rose by 5.74%, to 46.95 Hong Kong dollars.
LUZHU BIOTECH-B: SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2023
It is difficult to take a shortcut to 'ruisong,' and it is also difficult to support the commercialization of unique products. Green Bamboo Biology - B (02480) valuation.
For Lu Zhou Biotechnology, if shortcuts are not feasible, the company can only rely on its own fundamentals to attract market attention. However, the core shingles product has not yet been launched, and the future commercial prospects of the company are still uncertain.
No Data
No Data